Spanish Regulators Approve Phase 2 Trial of Oryzon’s Alzheimer’s Therapy

Spanish Regulators Approve Phase 2 Trial of Oryzon’s Alzheimer’s Therapy
Spanish regulators have signed off on Oryzon Genomics' plan to conduct a Phase 2 clinical trial of its Alzheimer's therapy ORY-2001. The ETHERAL trial, which will cover patients with mild to moderate forms of the disease, will be the first to assess the effectiveness of an epigenetic therapy for Alzheimer's. This approach involves regulating genes' function without altering their makeup. The trial will also assess the treatment's safety. Ninety patients are expected to take part in the study, whose objectives will include seeing if ORY-2001 can improve patients' memory and behavior. Researchers also want to know if it can improve cerebrospinal fluid biomarkers of the disease. Oryzon is expected to begin enrolling participants in the seco
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *